Your Macular Degeneration Risk Is Written in Your DNA.

Your retina is constantly cleaning up debris. Dead photoreceptors, lipid particles, proteins that have been damaged by light. This housekeeping is done by cells called microglia, which use a system called complement to identify and destroy garbage. Complement Factor H (CFH) acts as the brake on this system. It tells your immune cells when to stop cleaning. Without CFH working properly, your immune response overshoots. Your retina becomes inflamed even when it should be calm.

The Y402H variant, carried by roughly 30-40% of people of European ancestry, weakens CFH’s ability to regulate complement in the retina. People with this variant have a 3 to 4-fold increased risk of age-related macular degeneration. Your immune system cannot distinguish between useful cleanup and harmful inflammation. Drusen accumulate faster. The retinal pigment epithelium (the layer that supports your photoreceptors) starts to degenerate.

You might not feel this happening. Your vision loss is gradual. You notice words on a screen are blurry. Your face looks slightly distorted when you look at a familiar person. Central vision (the part you use to read or drive) deteriorates. You may not connect it to your immune system, but that is exactly what is happening in your retina.

Your photoreceptors are among the most metabolically active cells in your body. They consume oxygen at rates comparable to muscle during intense exercise. This constant energy demand requires a rich network of blood vessels delivering oxygen and glucose. VEGF is the master signal that builds and maintains these vessels. When VEGF signaling is strong, your retinal blood vessels are robust and perfused. When it is weak, your photoreceptors are starved.

The -634G>C variant, present in roughly 35% of the population, reduces VEGF expression in the retina. People with the C allele produce less VEGF and have reduced retinal perfusion. Your blood vessels are thinner and more fragile. Oxygen delivery to your photoreceptors drops. In response, your retina tries to grow new vessels (neovascularization), but these new vessels are weak and prone to leaking. This is how wet AMD develops.

You experience this as a sudden blur or distortion in your central vision. Straight lines may appear wavy (a symptom called metamorphopsia). You may see dark spots or flashes of light. Your vision loss may happen over days or weeks rather than the slow decline of dry AMD. This is your retina struggling to survive on inadequate blood supply.

Your photoreceptors operate under a paradox. They must absorb light constantly to see, but light drives oxidative reactions that generate free radicals. These free radicals, particularly superoxide, would destroy your cells in minutes if not neutralized. SOD2 (superoxide dismutase 2) is the primary enzyme that detoxifies superoxide inside your mitochondria, the energy factories of your photoreceptors. It is the first line of defense against oxidative damage.

The Val16Ala variant, carried by roughly 40% of the population in the homozygous form, produces a less efficient version of SOD2. People with the Ala16 variant have reduced mitochondrial antioxidant capacity and accelerated accumulation of oxidative damage in photoreceptors. Over decades, this adds up. Lipofuscin (a brown pigment of oxidized protein and lipid) accumulates in your retinal pigment epithelium. Your photoreceptors sicken. Drusen form. Central vision fades.

You experience this as a gradual dimming of your world. Colors seem less vibrant. You need more light to read. Your eyes feel tired more easily. You may have difficulty adjusting when you move from a bright room to a dim one. This is your photoreceptors struggling under a burden of oxidative stress they cannot clear.

Vitamin D is not just about bone health. Your retina has vitamin D receptors (VDR) on photoreceptors, retinal pigment epithelium, and immune cells. Vitamin D binding to VDR in the retina regulates inflammation, supports retinal cell survival, and modulates immune tolerance. When VDR signaling is compromised, your retina becomes more vulnerable to both immune attack and oxidative stress.

The FokI variant (which exists in both ff and FF forms) affects the length and activity of the VDR protein. Roughly 50% of the population carries the less efficient ff form. People with the ff genotype have reduced VDR signaling efficiency and impaired vitamin D responsiveness in the retina. Even if your blood vitamin D level is normal, your retinal cells may not be receiving the protective signal they need. Your retinal inflammation is harder to control. Your photoreceptors are more vulnerable to damage.

You might have adequate vitamin D levels on paper but still experience progressive retinal degeneration. Your retina is not responding normally to vitamin D signaling. It is as if your cells are resistant to the protective effects of the vitamin. Your vision loss accelerates despite supplementing with vitamin D.

MTHFR is a critical enzyme in the methylation cycle, the biochemical pathway that produces methyl groups needed for DNA repair, antioxidant recycling, and nitric oxide synthesis. Nitric oxide is essential for retinal blood vessel function and endothelial health. The C677T variant, carried by roughly 40% of people of European ancestry, reduces MTHFR enzyme activity by 40-70%. Your cells cannot produce enough methylfolate (the active form of folate) or regenerate antioxidants efficiently.

When MTHFR is compromised, homocysteine levels rise, damaging retinal blood vessels and reducing nitric oxide-dependent blood flow. Your retinal capillaries become stiff and leaky. Oxidative stress in your photoreceptors builds up because you cannot recycle antioxidants like glutathione. Your retina ages faster on two fronts: vascular insufficiency and oxidative burden.

You notice that your vision loss is accompanied by other signs of poor methylation: easy bruising, difficulty concentrating, mood instability, or slow wound healing. Your retina is not the only tissue suffering. Your whole vascular system is aging faster. You are more prone to cardiovascular disease. Your eyes decline in parallel with your overall vascular health.

APOE controls how your body transports lipids and cholesterol, including to your retina. Your retinal pigment epithelium constantly absorbs and recycles lipid-rich outer segments from your photoreceptors. APOE regulates this lipid trafficking. The APOE4 allele (one of three common forms: APOE2, APOE3, APOE4) is associated with impaired lipid metabolism and accumulation of lipids in the retina. People carrying APOE4 have a harder time clearing lipid debris.

People carrying at least one APOE4 allele have an increased risk of both dry and wet AMD, particularly when combined with CFH variants. Lipids accumulate under your retina as drusen. These drusen trigger inflammation and retinal degeneration. Your lipid metabolism is less efficient at every level: transportation, recycling, and clearance.

You may have normal cholesterol levels but still accumulate drusen rapidly because your retina is not clearing lipid efficiently. Your AMD progresses despite a healthy diet. You may also notice other signs of APOE4 metabolism: difficulty losing weight, tendency toward higher cholesterol despite diet, or cognitive changes as you age. Your retina is declining along with other tissue systems sensitive to lipid metabolism.